The second of a two-part perspective examining why clinical trial enrollment and representation outcomes are shaped long before the first patient is screened.

Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.

A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.

Hierarchical composite endpoints analyzed through pairwise comparisons more accurately reflect multifaceted treatment benefit than time-to-first-event composites, but transparent outcome prioritization, patient involvement in ranking, and reporting of Net Treatment Benefit remain underutilized despite their importance to interpretation.